SEQ-400

Last updated
SEQ-400
Vaccine description
Target Escherichia coli
Clinical data
Other namesSEQ400
Routes of
administration 		Unspecified [1]

SEQ-400 is a vaccine against urinary tract infections (UTIs) which is under development for potential medical use. [1] [2] [3] It is a vaccine against the Escherichia coli FimH adhesin protein, which is essential for bacterial infection. [3] The vaccine is being developed by Sequoia Sciences. [1] [2] As of September 2023, it is in phase 2 clinical trials. [1] [2] SEQ-400 is being developed for potential approval and use in the United States. [1]

Contents

See also

References

  1. 1 2 3 4 5 "SEQ 400". AdisInsight. 15 September 2023. Retrieved 26 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on SEQ-400 with Synapse". Synapse. 23 January 2025. Retrieved 26 February 2025.
  3. 1 2 "Why Do Urinary Tract Infections (UTI) Recur?". ASM.org. 3 May 2024. Retrieved 26 February 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.